Bafisontamab vs Rybrevant Faspro (amivantamab and hyaluronidase-lpuj)

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Non-Small Cell Lung Cancer

Shared mechanism: EGFR x c-MET · full Non-Small Cell Lung Cancer pipeline

Bafisontamab

Developed by Shanghai EpimAb Biotherapeutics

Phase 1/2 in Non-Small Cell Lung Cancerbispecific antibody
Weak signal

NCT03797391 · Phase 1/2 · status unknown

This was an open-label, non-randomized, single-arm dose-escalation and expansion study of EMB-01 in patients with advanced solid tumors, with no control group, so it cannot reliably show the drug's effect versus no treatment. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.

Reported efficacy

Maximum tolerated dose (MTD) (phase 1 only) (cycle 1 (1cycle = 28 days)); Adverse Events (AEs), and Serious Adverse Events (SAEs) (Screening up to follow-up (30 days after the last dose)); Overall Response Rate (ORR) (phase 2 only) (From the date fo dosing until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 48 months): Phase I dose-escalation/expansion of EMB-01 (EGFR/cMET bispecific): 2 patients had a partial response (1 confirmed) and 14 had stable disease as best response; disease control rate 42.1%. 1600mg QW was determined as the RP2D (recommended phase 2 dose). (mixed)

Result source: NCT03797391

Rybrevant Faspro (amivantamab and hyaluronidase-lpuj)

Marketed by Johnson & Johnson

Approved in Non-Small Cell Lung Cancerbispecific antibody
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

No aligned efficacy figure on record for this race.

Results for Non-Small Cell Lung Cancer

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointBafisontamabRybrevant Faspro (amivantamab and hyaluronidase-lpuj)
PFS, median—Not reported—Trial running · NCT05388669
OS, median—Not reported—Trial running · NCT05388669
ORR—Not reported—Trial running · NCT05388669
Duration of response, median—Not reported—Trial running · NCT05388669

PFS, median

Bafisontamab
—Not reported
Rybrevant Faspro (amivantamab and hyaluronidase-lpuj)
—Trial running · NCT05388669

OS, median

Bafisontamab
—Not reported
Rybrevant Faspro (amivantamab and hyaluronidase-lpuj)
—Trial running · NCT05388669

ORR

Bafisontamab
—Not reported
Rybrevant Faspro (amivantamab and hyaluronidase-lpuj)
—Trial running · NCT05388669

Duration of response, median

Bafisontamab
—Not reported
Rybrevant Faspro (amivantamab and hyaluronidase-lpuj)
—Trial running · NCT05388669
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Bafisontamab: no structured comparison results are available for Non-Small Cell Lung Cancer.

Rybrevant Faspro (amivantamab and hyaluronidase-lpuj): registry results are on file for Non-Small Cell Lung Cancer, but their comparison mappings are not yet available.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Bafisontamab's landscape · Rybrevant Faspro (amivantamab and hyaluronidase-lpuj)'s landscape